THC Redistribution: Your Drug Test Came Back Positive for THC But You Haven’t Used Cannabis in Weeks

When a client reports stopping cannabis use weeks ago and cannot understand why they tested positive, a defense attorney with pharmacokinetic training treats that account seriously, because the pharmacokinetics of THC provide a scientifically documented explanation for exactly this situation, one that most drug-testing programs, probation officers, and defense attorneys do not understand.

Why THC Is Different from Every Other Drug

Most drugs are water-soluble. They circulate through the bloodstream, get metabolized by the liver, and are excreted relatively predictably. Detection windows are short and reasonably well correlated with actual use.

THC does not behave this way. Delta-9-tetrahydrocannabinol is highly lipophilic, which means it is chemically attracted to fat tissue. When cannabis is consumed, THC is rapidly absorbed and preferentially deposited in the body’s fat stores throughout the body, where it can concentrate at high levels. Research has documented THC in human fat biopsies up to 28 days after last exposure, and in chronic heavy users positive urine samples have been reported up to 102 days into abstinence (Galhenage and Rodrigo, 2023).

The persistence of THC in blood is equally striking. A 2025 study in Clinical Chemistry (Fitzgerald et al., 2025) measured blood THC in 190 regular cannabis users after at least 48 hours of abstinence. The results are notable: 43 percent exceeded zero-tolerance cutoffs (at or above 0.5 ng/mL), 24 percent exceeded the 2 ng/mL per se threshold used by some states, and 5.3 percent exceeded the 5 ng/mL per se threshold, all after two or more days without use. The maximum observed baseline was 16.2 ng/mL. Critically, participants who exceeded these cutoffs showed no difference in driving-simulator performance from those below them, which means a blood THC number at these levels does not reflect impairment, a point with direct consequences in marijuana DWI cases.

Under normal conditions, THC passively diffuses from fat back into the bloodstream over time, following the drug’s notoriously long elimination half-life. That is why heavy users can test positive for weeks after stopping. What is less well understood, including by the courts and supervision programs that enforce testing conditions, is what happens when the body begins actively breaking down fat tissue. That process is called lipolysis, and it does not release THC at a slow, passive rate. It releases it in a surge.

The Science of Lipolysis and THC Redistribution

A 2009 study in the British Journal of Pharmacology, the paper that first systematically documented this phenomenon, examined what happens when the body’s fat-burning mechanisms are activated in subjects who have stored THC in their fat tissue.

The researchers used two lipolysis-triggering conditions: administration of adrenocorticotrophic hormone (ACTH) and 24-hour food deprivation. Both produced the same result. In rats repeatedly dosed with THC and then given a two-day washout, food deprivation significantly increased blood THC and THC-COOH compared with controls, and the increase correlated directly with plasma glycerol, a marker of active fat breakdown. Critically, adipocytes taken from the food-deprived animals contained less THC than those from non-deprived animals, direct evidence that the rise in blood levels came from fat-stored THC being released, not from new exposure.

The mechanism is straightforward. THC is bound to triglycerides within fat cells. When lipolysis is triggered, by fasting, by stress, by exercise, hormone-sensitive lipases break those triglycerides into free fatty acids and glycerol, and the THC sequestered in the cell is expelled along with them, enters the circulation, and produces measurable increases in blood and urine THC.

Human studies extended the finding. A 2013 study in Drug and Alcohol Dependence found that 35 minutes of moderate stationary cycling produced a statistically significant rise in plasma THC in 14 regular users, accompanied by increased free fatty acids and glycerol confirming that lipolysis had occurred. Body mass index tracked the size of the effect, and the authors concluded that exercise can elevate blood THC by releasing dormant fat-stored drug, with direct implications for interpreting blood THC in roadside and drug-testing contexts.

The effect is not universal or guaranteed. A 2014 study using subjects with lower body-mass indices found no significant changes with exercise or fasting, the likely explanation being that less body fat means less stored THC to redistribute. The effect is more pronounced in people with higher body fat and more extensive prior use, exactly the profile of the chronic user attempting to abstain.

Screening for Hemp and CBD Products

Defense counsel should also ask clients about hemp and cannabidiol (CBD) products, and here the important question is pharmacological, not legal. A product marketed as hemp or CBD can still contain enough THC to contribute to a positive result, and urine testing after hemp or CBD use can produce positive screens for several days (Odell et al., 2015; Gerace et al., 2021; Noor and Zhang, 2020). This is the same hemp-versus-marijuana problem that dogs and field tests cannot resolve, which we cover in our post on drug-dog alerts.

The legal line for these products is shifting. Texas has moved from a delta-9-only threshold toward a total-THC standard that measures delta-9 THC and THCA together on a dry-weight basis (25 TAC §300.101, effective March 31, 2026), a change under active litigation, with the related smokable-hemp restriction before the Texas Fifteenth Court of Appeals. At the federal level, Section 781 of H.R. 5371 replaces the 2018 Farm Bill definition with one that excludes intoxicating THC levels, effective November 12, 2026. Because the rules are moving, what protects a client is documentation, not a label: where the product was purchased, its packaging, a receipt, a lot number, and the manufacturer’s certificate of analysis. Those records let a toxicologist assess whether a THC-containing product could have contributed to a result, whatever the statute says on the day of the test.

What This Means for Someone on Bond or Probation

Texas bond and probation conditions routinely require random drug testing. A person with a history of cannabis use who stops upon arrest faces a real and scientifically documented risk of testing positive, not because of new use but because of lipolysis-driven redistribution of fat-stored THC.

The conditions most likely to trigger it include exercise, particularly high-intensity or prolonged cardio; fasting or significant caloric restriction; rapid weight loss through diet or illness; stress-induced lipolysis, since the ACTH pathway activates in response to psychological stress; and any combination of these.

Consider the profile: someone who used cannabis regularly, was arrested, and is now trying to do everything right. The legal situation creates stress. Sleep and eating are irregular. Exercise may have increased to manage anxiety or lose weight. Every one of those conditions promotes lipolysis, and with sufficient stored THC, lipolysis releases that drug back into circulation, where it shows up on a test. The test result is real. The positive is real. The implication that the person recently used cannabis is not.

The Defense and Testing Challenge

This is not an easy argument to make in a probation-violation hearing. The burden of proof in a Texas revocation is a preponderance of the evidence, so the court need only find it more likely than not that the person violated a condition. A positive test with a credible non-use explanation shifts the work of making that argument onto the defense, and making it requires understanding the science well enough to explain it to a judge who has almost certainly never considered it. It also requires confirming what the positive actually was: a screening immunoassay is not proof, and the confirmatory question, covered in our post on presumptive versus confirmatory drug testing, comes first.

Several factors matter for evaluating whether the explanation is viable in a specific case:

Timing relative to last use.  Redistribution is most pronounced in the days and weeks after cessation, when fat stores are still heavily loaded. Someone who stopped a week ago has far more redistributable THC than someone who stopped six months ago.

Body composition.  The effect is larger in people with higher body fat and more extensive prior use. A chronic heavy user with significant body fat who stops suddenly has a larger reservoir than an occasional user with low body fat.

The magnitude of the result.  A result just above the cutoff is more consistent with redistribution than a very high one. In the Fitzgerald study, a baseline of 16.2 ng/mL appeared in a participant abstinent at least 48 hours with no simulator impairment, whose metabolite profile marked her as a heavy chronic user at steady-state baseline rather than a recent smoker. Over a series of tests, the trajectory is often more informative than any single reading.

Corroborating circumstances.  Was the person exercising intensively, dieting aggressively, or under significant stress? Did they lose weight between the last negative and the positive? Documented lifestyle factors that promote lipolysis strengthen the argument.

Trend analysis.  If results are gradually declining over time, reflecting passive elimination of stored THC, an isolated spike within an otherwise declining trend is more consistent with redistribution than with new use. A toxicologist who can chart that trajectory argues with data rather than speculation.

The Limits of the Argument

This defense has real limits, and being honest about them is what separates a scientific explanation from a convenient one. Redistribution does not account for every positive test, and three patterns cut against it:

A very high result does not fit.  Redistribution of fat-stored THC produces modest elevations, often near the testing cutoff, not extreme readings. A result far above the cutoff points toward recent use, not a lipolytic release.

No genuine history of heavy prior use does not fit.  The mechanism depends on a reservoir of THC laid down in fat by sustained, heavy past use. Someone with little or no real use history has nothing to redistribute, so the explanation simply does not apply.

No triggering event does not fit.  The release is driven by active fat breakdown, from rapid weight loss, fasting or heavy caloric restriction, intense exercise, or major stress. A positive with none of those triggers in the picture points somewhere other than redistribution.

Put positively, the argument is credible precisely when the facts line up: a documented history of heavy use, a plausible trigger, and a result and trajectory that fit a declining reservoir rather than a fresh spike. Where those elements are missing, a responsible toxicologist says so. That candor is what makes the analysis expert evidence rather than an excuse.

What to Do If You Are on Supervision and Test Positive

If you are on bond or probation with drug-testing conditions and receive a positive THC result after a period of genuine abstinence, contact an attorney before any hearing is scheduled. Do not try to explain the science to the probation officer or the testing lab. Get counsel involved immediately.

Evaluating whether the redistribution explanation applies requires the actual test results over time, a documented history of cannabis use before the arrest, body-composition information, and the circumstances around the test: what was eaten, whether exercise occurred, what stress was present, and what weight has been doing.

The science is real. It is peer-reviewed, published in major pharmacology and clinical-chemistry journals, and it has direct implications for how positive tests should be read in the supervision context. Whether it can be deployed successfully in a specific case depends on the facts, the expert support, and the legal framework, but it is a legitimate argument, not a desperate one.

References

Fitzgerald RL, et al. Per Se Driving Under the Influence of Cannabis Statutes and Blood Delta-9-Tetrahydrocannabinol Concentrations following Short-Term Cannabis Abstinence. Clinical Chemistry 71(12):1225-1233 (2025).

Galhenage J, Rodrigo A. Prolonged detection of cannabis in urine of a consumer in a forensic hospital up to 102 days of abstinence, a case report. Psychiatry Research Case Reports 2:100089 (2023).

Gerace E, et al. Determination of cannabinoids in urine, oral fluid, and hair after repeated intake of CBD-rich cannabis by smoking. Forensic Science International 318:110596 (2021).

Gunasekaran N, et al. Reintoxication: the release of fat-stored THC into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology 158(5):1330-1337 (2009).

Noor A, Zhang F. Can cannabidiol use cause a false positive THC urine drug screen? In Toxicology Cases for the Clinical and Forensic Laboratory, ch. 11.2, 183-185. Academic Press (2020).

Odell MS, et al. Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use. Forensic Science International 249:173-180 (2015).

Contact Deandra Grant Law

Drug-testing conditions attached to bond or probation are enforced aggressively, and a positive result can move toward revocation before any scientific challenge is mounted. If you or someone you know is facing a positive THC test under court supervision and there is a credible basis to argue the result reflects redistribution rather than recent use, defense counsel with genuine forensic-science training needs to be involved immediately.

Deandra Grant Law brings ACS-CHAL Forensic Lawyer-Scientist credentials and a Master of Science in Pharmaceutical Science to this analysis. The pharmacokinetic argument, the lipolysis mechanism, the redistribution timeline, the body-composition factors, and the trend analysis of test results, requires scientific training to evaluate and present. This firm has that training. Call (214) 225-7117 or visit texasdwisite.com for a confidential consultation.

About the Authors

Deandra Grant, J.D., M.S. is the Managing Partner of Deandra Grant Law and an ACS-CHAL Forensic Lawyer-Scientist who teaches the ACS forensic chromatography and drug-analysis courses at Axion Analytical Labs and serves on the faculty of the Robert F. Borkenstein Drug Course at Indiana University. She holds a Master of Science in Pharmaceutical Science (Forensic Science Concentration) from the University of Florida College of Pharmacy and a Graduate Certificate in Forensic Toxicology from UF’s College of Veterinary Medicine, and she chairs the DUI Defense Lawyers Association’s Board Certification program.

Sol Bobst, Ph.D., DABT is a board-certified toxicologist (Diplomate, American Board of Toxicology) and the founder of ToxSci Advisors LLC. Dr. Bobst provides forensic toxicology consulting, expert-witness testimony, and scientific review to attorneys and organizations across the United States, with expertise in analytical toxicology, drug metabolism, and the interpretation of drug-testing results.

This post is general legal and scientific information for educational purposes, not legal advice, and it describes an area of hemp law that is actively changing. Citations and legal details should be verified against current sources before being relied on in any filing.